Summary Differential drug response in a human cell line panel representing defined types of cytotoxic drug resistance was measured using the non-clonogenic fluorometric microculture cytotoxicity assay (FMCA) 
One of the largest drug discovery efforts in the field of cancer therapy has been pursued by the Developmental Therapeutics Program (DTP) at the National Cancer Institute (NCI) starting in 1955. Strategies for identification of novel chemotherapeutic agents at NCI (1955-85) have previously relied predominantly on the in vivo L1210 and P338 murine leukaemia models and certain other transplantable tumour models (Goldin et al., 1981; Boyd, 1993) . The early success in the discovery of antileukaemic activity of alkylating agents, anti-metabolites and vinca alkaloids contributed to the early and persistent focus on the animal leukaemia models as preclinical drug discovery tools (Grindley, 1990) .
However, during the past decade there has been a growing and continuing concern with the narrow spectrum of antitumour activity of available drugs and an increasing dissatisfaction with the clinical results for many of the most promising new investigational drugs (Marsoni et al., 1987) . Consequently, in 1985, the NCI began to phase out its in vivo P388 mouse leukaemia screen to replace it with a panel of cell lines (currently > 60) representing the major forms of human cancer (Alley et al., 1988) . A semiautomated non-clonogenic in vitro assay was selected for the analysis of growth inhibition and cytotoxicity (Monks et al., 1991) . The principal aim was to identify compounds with diseasespecific activity followed by evaluation in vivo, using the same cell lines as xenografts, and initiation of diseaseoriented phase I-II trials.
The approach was based on the belief that subpanel activity in vitro would predict the disease-specific activity in the clinic (Monks et al., 1991) . The differential drug activity information provided by the panel has indeed been shown to be 'drug-specific', i.e. it detects specific patterns of in vitro response of agents with similar mechanisms of action when tested over the 60 cell line panel (Paull et al., 1989) . This 'fingerprint' can be further used to classify the agents as being related to specific groups (e.g. anti-metabolites, alkylators, topoisomerase II inhibitors) by the use of correlation analysis (Paull et al., 1989) or advanced neural network (NN) computing (Weinstein et al., 1992) . The NN classifier performed better than the traditional statistical methods, giving only 8% incorrect classifications when 141 drugs with known mechanisms of action were separated into six different predefined mechanistic groups (Weinstein et al., 1992) .
Although, the ability to detect 'disease-specific activity' is yet to be demonstrated (Weisenthal, 1992) , this unprecedented approach clearly illustrates the potential value of comparing cell lines of different drug sensitivities for identification of anti-cancer agents of novel structure and mechanism of action. The approach for cell line panel analysis of differential growth inhibition and cytotoxicity developed by the NCI scientists (Paull et al., 1989; Weinstein et al., 1992; Boyd and Paull, 1995) may also become useful for limited-scale drug evaluation at single research departments.
In parallel with the change in drug discovery strategies, research activities in the area of drug resistance have revealed several specific cellular mechanisms of resistance to currently available anti-cancer drugs, which may, at least partly, be responsible for the dismal outcome of therapy for many types of tumours (Van Kalken et al., 1991) . These mechanisms encompass overexpression of transport molecules such as the P-glycoprotein (P-gp) and multidrug resistance-associated protein (MRP), glutathione (GSH)-dependent increased activity of cellular detoxification systems, altered function of nuclear target enzymes such as topoisomerase II (topo II) as well as altered tubulin binding/function (Beck, 1987; Beck et al., 1987; Kramer et al., 1988; Dalton et al., 1989a; Baas et al., 1990; Hall and Cattan, 1991; Hochhauser and Harris, 1991; Cole et al., 1992; Ohta et al., 1993) . These resistance phenotypes have been identified using cell lines selected after exposure to various anti-tumour agents and thus constitute useful in vitro models not only for studying the molecular mechanisms of drug resistance but also for the identification and characterisation of new pharmacological agents for cancer treatment.
With this background, the present study was undertaken to investigate the feasibility of using a limited number of human tumour cell lines representing defined types of cytotoxic drug resistance for the initial evaluation and preliminary mechanistic classification of anti-cancer agents. -937-vcr (Botling et al., 1994) , the small-cell lung carcinoma (SCLC) cell line NCI-H69 and its subline NCI-H69AR (American Type Culture Collection; ATCC, Rockville, MD, USA), the renal adenocarcinoma cell line ACHN (ATCC) and the leukaemia cell line CCRF-CEM and its subline CEM/VM-1 (kind gifts from WT Beck, Department of Pharmacology, College of Medicine, University of Tennessee, Memphis, TN, USA).
The 8226/Dox4O was selected for doxorubicin (Dox) resistance and shows the classical MDR phenotype with overexpression of P-gp 170 (Dalton et al., 1986 (Dalton et al., , 1989b . The 8226/LR5 was selected for melphalan (Mel) resistance, proposed to be associated with increased levels of glutathione (GSH; Bellamy et al., 1991; Mulcahy et al., 1994) . The U-937-vcr was selected for vincristine (Vcr) resistance, proposed to be tubulin associated (Botling et al., 1994) . The H69AR, selected for Dox resistance, expresses a MDR phenotype proposed to be mediated by MRP (Mirski et al., 1987; Slovak et al., 1993) . The CEM/VM-1, selected for teniposide (VM/26) resistance, expresses the atypical MDR phenotype, which is proposed to be topo II associated (Danks et al., 1987 (Danks et al., , 1988 . The drug resistance of the primary resistant ACHN cell line is probably multifactorial (Nygren and Larsson, 1991) . The proposed mechanisms of resistance are summarised in Table I. The cells were grown in culture medium RPMI-1640 (HyClone, Cramlington, UK), supplemented with 10% heatinactivated fetal calf serum (HyClone), 2 mM glutamine, 50 ,ug ml-' streptomycin and 60 jug ml-' penicillin (HyClone). The 8226/Dox4O cells were treated once a month with 0.24 ,ug ml-'of Dox and the 8226/LR5 cells at each change of medium with Mel at 1.53 jug ml-'. The U-937-vcr was continuously cultured in the presence of 10 ng ml-' Vcr and the NCI-H69AR was alternately fed with drug-free medium and medium containing 0.46 ,ug ml-' Dox. The CEM/VM-1 cell line was cultured in drug-free medium and could be grown for 3 -4 months without loss of resistance. Every 2-3 months the cell lines were tested for maintained cross-resistance phenotype with a control plate containing Mel, Dox and Vcr. Growth and morphology were monitored on a weekly basis.
Drugs and exposure
The ten cell lines were tested against a total of 37 different cytotoxic drugs, using the fluorometric microculture cytoMechanism-based screening of anti-cancer drugs S Dhar et al I 889 toxicity assay (FMCA; Larsson and Nygren 1989, 1990 In Figure 1 the principal features of the drug-response analysis procedure are shown. The concentration-response curves for the topo II inhibitor Epi (Figure la) and the alkylating agent Mel (Figure lb) for the ten cell line panel are displayed. Figure Ic and (Jensen et al., 1991) and shows low correlations to the topo II poisons, including those of the chemically similar anthracycline group of compounds. Thus, high correlation seems to indicate a similar mode of action.
In Table V correlations were 100%, 92%, 88% and 52% for the topo II inhibitors, alkylators, tubulin-active agents and anti-metabolites respectively. The results confirm the ability of the system to detect principal mechanisms of action. Next, we employed the NN strategy to further test the concept of predicting drug mechanisms of action from the drug-response relationships obtained in the cell line panel (Figure 2 ). The 32 drugs representing these classes (Table II) were divided into eight groups, seven drugs in each group and trained independently to produce eight networks, NI to N8. In Table VI , the performance of the networks is shown for patterns independent of the data used to train the network. The results show a good ability to classify the drugs into the four categories with 29/32 (91 %) correct classifications. Moreover, the probability of the 'winning' output neuron was generally high and well separated from the losing neurons, suggesting a robust classification system. The misclassifications were AraC and taxol, which were classified as alkylating drugs, and mitomycin C, which was classified as an anti-metabolite. The delta patterns of aclarubicin, suramin, prednisolone and cremophore EL with miscellaneous mechanism of action as well as the topoisomerase I inhibitor topotecan were tested using a network allowing also for classification into a fifth extra output category representing 'other' mechanisms of action. This network NN9 was trained with the 32 patterns of drugs with known mechanism of action. In this analysis all four miscellaneous drugs and topotecan were assigned to the 'other' category (not shown). Figure 2 The principle for NN analysis of a hypothetical topo II-targeted drug is shown. NN differs from conventional statistical methods in that it learns from a set of pattern examples (training set) to develop the ability to correctly classify new patterns. Ten inputs consisting of the deltas (deviations from mean log IC50) for the different cell lines are transmitted to an input layer with ten input neurons. The input layer was connected to a hidden layer with 28 neurons (matching the number samples used for training the NN), which in turn is connected to the output layer with four output neurons. The neuron with the highest probability (weight on each output neuron/total weight on output neurons) is considered to be the winning neuron. The four outputs selected were: topo II inhibitors, alkylataing agents, tubulin-active agents and anti-metabolites.
Mechanism-based screening of anti-cancer drugs S Dhar et al 
Discussion
Rapid in vitro evaluation and prioritisation of drugs of novel structure for further research are important initial steps in the drug discovery process. Experience with the NCI drug discovery in vitro screen has shown that the drugg-response curves obtained from a spectrum of different cell lines contain rich information on mechanism of action that could be used for this purpose (Paull et al., 1989; Weinstein et al., 1992) .
In the present study we demonstrate the feasibility of using drug-response curves from a limited number of human cell lines representing defined types of drug resistance to provide preliminary information on mechanism of drug action of cytotoxic drugs. The inclusion of cell lines with different mechanisms of resistance in the panel may have contributed to this ability by increasing the diversity of drug sensitivity across the panel. Correlation analysis showed a good ability to recognise drugs with similar mechanism of action even among drug classes such as topo II inhibitors and tubulinactive agents, which share common mechanisms of resistance (i.e. P-gp and MRP). Moreover, topo II inhibitors were readily identified and anthracycline aclarubicin, for which topo II is not the cytotoxic target (Jensen et al., 1991) , could be distinguished from the group. A good ability of the correlation analysis to detect mechanisms of action was also observed for alkylating agents and tubulin-active agents. Anti-metabolites, on the other hand, generally showed lower within-group correlations, probably reflecting a high degree of heterogeneity with respect to actual mechanism in this group (Weinstein et al., 1992; van Osdol et al., 1994) . For example, in the correlation analysis, both AraC and cladribine were associated with alkylating agents. In fact, cladribine has shown a high degree of correlation to alkylating agents in primary cultures of haematological tumour cells (Nagourney et al., 1993) . However, in the neural network analysis only AraC of the anti-metabolites was misclassified as an alkylator. In the case of AraC, simple visual inspection of the correlation graph clearly indicated that the failure even to obtain IC30 values in six of the cell lines in combination with high activity against CEM and U-937 cell lines gave a high correlation coefficient despite a visual lack of correspondence of the majority of the data points. Mitomycin C was also misclassified as a topo II inhibitor by the NN. In this case the correlation analysis ranked six out of eight alkylators among the top ten drugs when mitomycin C was used as the seed compound. It should also be noted that mitomycin C was the only alkylator in the drug database alkylating at the N-2 position of guanine (van Osdol et al., 1994) .
The third misclassification was taxol, which was assigned to the alkylator category. This may partly be due to the paradoxical taxol sensitivity of the MRP-expressing H69AR cell line, which was 100-fold more sensitive to the drug compared with parental NCI-H69 cells (not shown Increasing the smoothing factor to 0.4 showed a high probability (0.999) for the AA category.
reason for this paradoxical sensitivity remains to be elucidated. Despite this, all tubulin-active drugs were found among the ten drugs with the highest correlation coefficients when correlations to taxol were examined and ranked. Thus, by combining NN analysis, correlation analysis and visual inspection of the correlation graphs, an initial guess on mechanistic type may be made with some confidence, which can help direct further research. However, this approach will require prospective confirmation on additional sets of drugs. In addition to the mechanistic classification by comparison of drug-specific patterns of drug activity, the present cell line panel can also provide information on the susceptibility of drugs to defined mechanisms of resistance at the molecular level. The calculation of simple ratios of resistant over parental cell line IC50 values, 'resistance factors', may provide this complementary information. Although, the mechanisms of resistance have been established using tumour cell lines they may be of clinical importance. The present system may also provide a tool for structure-activity relationship (SAR) studies by giving a simultaneous comparison of quantitative (i.e. relative potency) and qualitative (i.e. presumed mechanism of action) features among a selected group of compounds (Boyd and Paull, 1995) . This approach requires no prior knowledge of the structure of the molecular target per se. From a practical point of view, using the method described, 6-9 drugs can easily be prepared and analysed on all ten cell lines each week by a single technician. This relatively limited expenditure of resources and workload may also allow single institutions to acquire this capacity.
In the present study we employed PNN instead of classical back propagation networks as used by Weinstein et al. (1992) . The backward propagation type is highly complex and involves many small modifications of the system parameters that gradually improve system performance. The major difference between PNN and backward propagation is that the sigmoid activation function of the latter is replaced by a statistically derived one in the former (Specht, 1990) . The main operational advantage of PNN is that training is very easy and quick (instantaneous) and sparse data are adequate for network performance. The shape of the decision surface can be made as complex as necessary, or as simple as desired, by choosing appropriate values of only one parameter (the smoothing factor; Specht, 1990) .
Discovery of new molecular targets and/or mechanisms of resistance is one of the major objectives of the present research programme. This can to some extent be accomplished by using the drug database as described. However, development of a complementary database of differential molecular expression across the cell line panel may add to this objective by providing molecular correlates to the drug activity patterns. By seeding the drug database with acrosscell line quantitative patterns of molecular expression/ function of cell growth-regulatory and/or drug sensitivity or resistance determinants (in the mean-graph format), matching drug activity patterns can be identified and provide clues on the nature of the particular drug-target interaction. Indeed, the NCI reported very promising results when their drug database was searched using P-gp expression (Alvarez et al., 1995) and function (Lee et al., 1994) as the seed patterns. High correlations of measured across-panel patterns of P-gp function to drug-response patterns of known P-gp substrates have also been observed using the present system (not yet published).
The above approach might provide important information on the molecular pharmacology of drug interactions with known target molecules. (Weinstein et al., 1992) . In the present study the predictive accuracy of the NN was reasonably good when adhenrng to the quality criteria established for successful assays.
Furthermore. with the present approach, only drugs wAith a cytotoxic mode of drug action are readily amenable to analysis due to the relatively short assay time. Thus. compounds with strictly antiproliferative effects might be missed. Partial remedy for this may be to use IC-, values. which were used for three of the drugs in the present study. or increased assay time. Increasing assay time will increase the impact of antiproliferative effects especially for slowly proliferating cell lines (Larsson and Nygren. 1989). However. for the anti-metabolites. for which time-dependent antiproliferative effects may be a characteristic, all these drugs produced an ICWo value in at least four cell lines.
Finally. for many drugs the mechanism of action is only tentatively defined and may be different and mixed depending on the cell system used. Owing to the limited number of drugs and drug classes tested in the present study, only four mechanistic categories were selected as output categories in the analysis. However. despite these potential limitations the patterns of these four groups at least were fairly well separated to allow good predictions in the majority of cases also when the fifth category for unknown or other mechanism of action was added. Differentiation of these mechanistic categories into subgroups may be possible as the database expands and new knowledge on mechanisms of action is added. Additional cell lines with novel mechanisms of resistance may also be added to the panel in the future.
In summary. new anti-cancer drugs with improved efficacy and a broader spectrum of activitv are desperately needed. The present evaluation system may provide important initial information not only on anti-tumor efficacy and mechanistic classification of each drug. but. also on the susceptibility to defined mechanisms of resistance at the molecular level. Moreover. this in vitro system may also serve as a practical tool for bioassay-guided drug design. However. further prospective evaluation is required to assess the utility of these potential applications.
